KRAS wild-type CRC harboring mutations in HRAS, NRAS, PIK3CA, PIK3CD, PIK3CG, RALGDS, RGL1-3, BRAF, ARAF, or RAF1 were excluded from the analysis because mutations in these genes directly affect KRAS-mediated signaling. This evidence concerns the gene BRAF and colorectal carcinoma.